Comparison of Two Gelatin and Thrombin Combination Hemostats in a Porcine Liver Abrasion Model
Authors:
- Kevin M. LewisKLKevin M. Lewis
- Holly D. AtleeHAHolly D. Atlee
- Angela J. MannoneAMAngela J. Mannone
- Joseph DwyerJDJoseph Dwyer
- Lawrence LinLLLawrence Lin
- Andreas GoppeltAGAndreas Goppelt
- Heinz RedlHRHeinz Redl
Open Access
- 20 March 2013
- journal article
- research article
- Published by Taylor & Francis in Journal of Investigative Surgery
- Vol. 26 (3) , 141-148
Abstract
Background: Surgical hemostasis is achieved using adjunctive hemostats when conventional methods fail. Objective: This study compares the effectiveness of two adjunctive gelatin-thrombin hemostats. Hypothesis: To determine effectiveness, hemostats were compared in vivo, in vitro, and using scanning electron microscopy (SEM). Methods: In vivo, a heparinized porcine liver abrasion model was used to compare hemostatic success, degree of bleeding, and blood loss at 2, 5, and 10 minutes post-treatment. In vitro, thrombin in the supernatant of each hemostat and Red Blood Cells (RBC'S) in the supernatant of clots formed by each was compared. Results: Ultrastructure of one gelatin was smooth and the other stellate. In vivo, smooth gelatin provided superior hemostatic success at 5 (85% vs. 60%; OR: 5.3; 95% CI: 1.66 to 17.9) and 10 mins (72.5% vs. 47.5%; OR: 5.0; 95% CI: 1.55 to 16.1). Smooth gelatin had a statistically different degree of bleeding at 5 (0.58 ± 0.87 [Mean ± SD] vs. 1.03 ± 1.12; OR: 3.36; 95% CI: 1.34 to 8.41) and 10 mins (1.13 ± 1.14 vs. 1.65 ± 1.05; OR: 3.87; 95% CI: 1.62 to 9.21). Mean blood loss was less with smooth gelatin at 2 (0.07 ± 0.19 vs. 0.13 ± 0.63 ml/min), 5 (0.04 ± 0.13 vs. 0.23 ± 0.45 ml/min), and 10 mins (0.09 ± 0.24 vs. 0.21 ± 0.32 ml/min). In vitro, supernatant of smooth gelatin had significantly less thrombin (6.81 vs. 10.9 IU/ml, p = .001), and significantly less RBC's than stellate gelatin (0.07 vs. 0.09 × 106/ul, p = .0085). Conclusion: Smooth gelatin has an increased ability to retain thrombin and RBC's in vitro which may explain why it provides superior hemostatic effectiveness, superior control of bleeding, and greater reduced blood loss in vivo.Keywords
This publication has 25 references indexed in Scilit:
- State-of-the-Art Review: Hemostats, Sealants, and Adhesives II: Update As Well As How and When to Use the Components of the Surgical ToolboxClinical and Applied Thrombosis/Hemostasis, 2010
- A Comprehensive Review of Topical Hemostatic AgentsAnnals of Surgery, 2010
- Reducing blood loss at myomectomy with use of a gelatin-thrombin matrix hemostatic sealantFertility and Sterility, 2009
- The relationship between heparin level and activated clotting time in the adult cardiac surgery populationPerfusion, 2009
- Comparison of gelatine matrix‐thrombin sealants used during laparoscopic partial nephrectomyBJU International, 2008
- Phase 3, randomized, double-blind study of plasma-derived human thrombin versus bovine thrombin in achieving hemostasis in patients undergoing surgeryCurrent Medical Research and Opinion, 2008
- A Phase 3, Randomized, Double-Blind Comparative Study of the Efficacy and Safety of Topical Recombinant Human Thrombin and Bovine Thrombin in Surgical HemostasisJournal of the American College of Surgeons, 2007
- Antihuman Factor V Antibodies After Use of Relatively Pure Bovine ThrombinThe Annals of Thoracic Surgery, 2005
- Controlled clinical trial of a novel hemostatic agent in cardiac surgeryThe Annals of Thoracic Surgery, 2000
- Human prothrombin metabolism in normal man and in hypocoagulable subjectsJournal of Clinical Investigation, 1969